Monocyte Subsets and Related Chemokines in Carotid Artery Stenosis and Ischemic Stroke
Authors:
- Gerrit M. GrosseGGGerrit M. Grosse
- Walter J. Schulz-SchaefferWSWalter J. Schulz-Schaeffer
- Omke E. TeebkenOTOmke E. Teebken
- Ramona SchuppnerRSRamona Schuppner
- Meike DirksMDMeike Dirks
- Hans WorthmannHWHans Worthmann
- Ralf LichtinghagenRLRalf Lichtinghagen
- Gerrit MayeGMGerrit Maye
- Florian P. LimbourgFLFlorian P. Limbourg
- Karin WeissenbornKWKarin Weissenborn
Open Access
- 23 March 2016
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (4) , 433
Abstract
Carotid stenosis (CS) is an important cause of ischemic stroke. However, reliable markers for the purpose of identification of high-risk, so-called vulnerable carotid plaques, are still lacking. Monocyte subsets are crucial players in atherosclerosis and might also contribute to plaque rupture. In this study we, therefore, aimed to investigate the potential role of monocyte subsets and associated chemokines as clinical biomarkers for vulnerability of CS. Patients with symptomatic and asymptomatic CS (n = 21), patients with cardioembolic ischemic strokes (n = 11), and controls without any cardiovascular disorder (n = 11) were examined. Cardiovascular risk was quantified using the Essen Stroke Risk Score (ESRS). Monocyte subsets in peripheral blood were measured by quantitative flow cytometry. Plaque specimens were histologically analyzed. Furthermore, plasma levels of monocyte chemotactic protein 1 (MCP-1) and fractalkine were measured. Intermediate monocytes (Mon2) were significantly elevated in symptomatic and asymptomatic CS-patients compared to controls. Mon2 counts positively correlated with the ESRS. Moreover, stroke patients showed an elevation of Mon2 compared to controls, independent of the ESRS. MCP-1 levels were significantly higher in patients with symptomatic than in those with asymptomatic CS. Several histological criteria significantly differed between symptomatic and asymptomatic plaques. However, there was no association of monocyte subsets or chemokines with histological features of plaque vulnerability. Due to the multifactorial influence on monocyte subsets, the usability as clinical markers for plaque vulnerability seems to be limited. However, monocyte subsets may be critically involved in the pathology of CS.Keywords
This publication has 38 references indexed in Scilit:
- Relevance of Distinct Monocyte Subsets to Clinical Course of Ischemic Stroke PatientsPLOS ONE, 2013
- Toward a Refined Definition of Monocyte SubsetsFrontiers in Immunology, 2013
- Fractalkine Is Expressed in Early and Advanced Atherosclerotic Lesions and Supports Monocyte Recruitment via CX3CR1PLOS ONE, 2012
- Local Gene Silencing of Monocyte Chemoattractant Protein-1 Prevents Vulnerable Plaque Disruption in Apolipoprotein E-Knockout MicePLOS ONE, 2012
- SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subsetBlood, 2011
- CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's diseaseJournal of Neuroinflammation, 2011
- A role for spleen monocytes in post-ischemic brain inflammation and injuryJournal of Neuroinflammation, 2010
- Prevalence of Asymptomatic Carotid Artery Stenosis in the General PopulationStroke, 2010
- Contemporary Results of Carotid Endarterectomy for Asymptomatic Carotid StenosisStroke, 2010
- Dominant‐negative mutation of monocyte chemoattractant protein‐1 prevents vulnerable plaques from rupture in rabbits independent of serum lipid levelsJournal of Cellular and Molecular Medicine, 2008